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Edited by Robert BaroukiAbstract Knockout of the translation inhibitor 4E-BP1 induces
an overexpression of uncoupling protein-1 (UCP1) [Nature
Medicine 7 (2001) 1128]. A possible inverse control of UCP1 and
4E-BP1 expressions in mouse brown adipose tissue was inves-
tigated. Cold-exposure, which increases the expression of UCP1,
decreased that of 4E-BP1 mRNA in wild type but not in
b1=b2=b3-adrenoceptor knockout mice. Administration of the b3-
adrenoceptor agonist CL 316 246 decreased 4E-BP1 mRNA by
75% and protein by 41% after 6 and 48 h, respectively. Our data
are the ﬁrst report of a regulation by the b3-adrenoceptor of 4E-
BP1 expression. They support a role of the latter in adaptive
thermogenesis.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Brown adipose tissue1. Introduction
Brown adipose tissue (BAT), which is involved in the control
of body temperature and body weight via non-shivering and
diet-induced thermogenesis, plays an important role in mam-
malian energy balance. It contains a unique mitochondrial
uncoupling protein, termed uncoupling protein-1 (UCP1),
which produces heat by uncoupling oxidative phosphoryla-
tion. BAT also expresses the peroxisome proliferator-activated
receptor c (PPARc) co-activator-1 (PGC-1), sharing this fea-
ture with the heart and skeletal muscle of cold-exposed ro-
dents. PGC-1 stimulates the transcriptional activity of PPARc
and thyroid hormone receptors on UCP1 expression in BAT
[2]. Cold-exposure results in an activation of the BAT
sympathetic nervous system (SNS), which stimulates, via the
b-adrenoceptors, PGC-1 and UCP-1 expression [2].* Corresponding author. Fax: +41-22-379-5502.
E-mail address: lehr6@etu.unige.ch (L. Lehr).
Abbreviations: BAT, brown adipose tissue; UCP1, uncoupling protein-
1; PPARc, peroxisome proliferator-activated receptor c; PGC-1,
PPARc co-activator-1; eIF4F, eukaryotic initiation factor 4F; 4E-
BP, eIF4E binding protein; KO, knockout; WAT, white adipose tissue;
WT, wild type; SNS, sympathetic nervous system; PKA, protein kinase
A; MAPK, mitogen-activated protein kinase
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doi:10.1016/j.febslet.2004.08.081The initiation phase of mRNA translation is a key step in
the control of protein synthesis. It involves the recognition of
the mRNA 50 cap structure by the eukaryotic initiation factor
4F (eIF4F) cap-binding complex. This complex consists of 3
subunits: eIF4A, eIF4E and eIF4G [3]. The activity of eIF4E is
regulated by its interaction with a family of three inhibitory
proteins, the eIF4E binding proteins (4E-BPs). In its under-
phosphorylated form, 4E-BP1 binds to eIF4E and prevents the
formation of the eIF4F complex, thus inhibiting cap-depen-
dent translation. 4E-BP1 hyper-phosphorylation causes its
dissociation from eIF4E, which can form a productive eIF4F
complex [4,5]. It has been shown that the anabolic eﬀects of
hormones, like insulin and growth hormone, or of nutrients
implicate the phosphorylation of 4E-BP1 in various tissues
[6,7].
4E-BP1 knockout (4E-BP1 KO) mice were recently re-
ported. They were expected to display a global increase in
tissue protein synthesis. The phenotype of the 4E-BP1 KO
mice was, however, a surprise. The inguinal and retro-perito-
neal white adipose tissues (WAT) of 4E-BP1 KO mice were
found to contain an increased number of multilocular adipo-
cytes, which are characteristic of BAT. Consistent with this,
WAT PGC-1 protein and UCP1 mRNA levels, as well as
whole body energy expenditure, were increased, resulting in a
decrease in body fat mass. 4E-BP1 therefore seems to be
a speciﬁc repressor of UCP1 expression and can be considered
a new player in the control of adipose tissue development and
energy homeostasis [1].
Since the activation of the BAT SNS by cold-exposure re-
sults in an increase in the expression of the thermogenic
partners PGC-1 and UCP1 [2], it was hypothesized that the
BAT SNS also acts on 4E-BP1 expression in a way that would
facilitate the increase in thermogenesis. The aim of the present
study was therefore to investigate the possible downregulation
of the mouse BAT 4E-BP1 mRNA and protein expressions by
the b-adrenergic system.2. Materials and methods
2.1. Mice
Animals were treated in accordance with our institutional guide-
lines. Three month-old female C57BL/6J wild type (WT) or b3-
adrenoceptor KO mice generated in our laboratory [8] were used. The
b1=b2-adrenoceptor KO mice [9] were kindly provided by Dr. B.K.blished by Elsevier B.V. All rights reserved.
Fig. 1. Northern blot quantiﬁcation of UCP1 and 4E-BP1 mRNA in
the BAT of C57BL/6J female mice maintained at 24 C (controls) or
exposed to 6 C for 48 h. The results are means ± S.E. of arbitrary
values normalized using the corresponding 18S rRNA values. They are
expressed as percent of the controls. n ¼ 6; *P < 0.05 and
***P < 0.005 vs respective control values.
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The b1=b2=b3-adrenoceptor KO (b-less) mice were generated in our
laboratory [10] by intercrossing our b3-adrenoceptor KO [8] with the
b1=b2-adrenoceptor KO mice [9]. WT and KO colonies were on the
same mixed genetic background (129SvJ, FVB/N, C57BL/6J and
DBA/2 for b1=b2-adrenoceptor KO mice and the same plus 129 Sv/ev
for b-less mice). All animals were maintained at 24 C on a 12 h/12 h
light/dark cycle (7:00–19:00), with free access to water and standard
laboratory chow diet (Nordos, Cergy, France) and caged individually
during the experimental periods. In one experiment, C57BL/6J
mice were injected with saline or CL 316243 (1 lg/g of body weight)
intra-peritoneally.
2.2. Northern blots
The mice were killed by cervical dislocation and the interscapular
BAT was carefully dissected and quickly frozen in liquid nitrogen.
Total RNA was puriﬁed by the method of Chomczynski and Sacchi
[11], and 15 lg of RNA was electrophoresed in 1% agarose gel con-
taining formaldehyde and transferred according to standard protocols.
The probes used were full length mouse UCP1 cDNA (GenBank Ac-
cession No. U63418) and a 701 bp 4E-BP1 PCR probe, position 22–
722 (GenBank Accession No. NM007918). The probes were labeled by
random priming with [a-32P] dCTP (Amersham International, Bucks,
UK) to a speciﬁc activity of approximately 1 · 109 d.p.m./lg DNA.
Hybridizations were performed using Quickhyb solution (Stratagene
Inc, La Jolla, CA) as previously described [12]. Subsequent hybrid-
ization of the blots with a [a-32P] ATP labeled synthetic oligonucleo-
tide speciﬁc for the 18S rRNA subunit was used to correct for the
diﬀerences in the amounts of RNA loaded onto the gels. Blots were
exposed at )80 C to Hyperﬁlm ECL ﬁlms (Amersham International,
Bucks, UK). RNA levels were quantiﬁed by scanning photodensi-
tometry of the autoradiograms using IMAGEQUANT Software ver-
sion 3.3 of Molecular Dynamics (Sunnyvale, CA).
2.3. Real-time PCR
Oligo-dT ﬁrst strand cDNA were synthesized using the Superscript
II RNase H Reverse Transcription kit (Invitrogen, Life technologies,
Basel, Switzerland) according to the manufacturer’s instructions. Real-
time PCR was performed using ABI rapid thermal cycler system and a
SYBR Green PCR master mix according to the manufacturer’s in-
structions. Cyclophilin A was used as a control to account for any
variations due to the eﬃciencies of the reverse transcription and PCR.
UCP1 oligonucleotide primers used were: upstream 50-cgatgtccatgta-
caccaagga-30 and downstream 50-ttgtggcttcttttctgcga-30, covering
the nucleotides 996–1063 of UCP1 cDNA (GenBank Accession No.
U63418). 4E-BP1 oligonucleotide primers used were: upstream 50-
ggcggcacgctcttca-30 and downstream 50-gaaatttctgatggagtgtcgga-30,
covering the nucleotides 120–195 of 4E-BP1 cDNA (GenBank
Accession No. NM007918). Cyclophilin A oligonucleotide primers
used were: upstream 50-caaatgctggaccaaacacaa-30 and downstream 50-
ccatccagccattcagtcttg-30, covering the nucleotides 343–412 of cyclo-
philin A (GenBank Accession No. XM355936). The conditions of
PCR were a step at 50 C for 2 min followed by a denaturing step at 95
C for 10 min and by 50 cycles at 95 C for 15 s and 60 C for 1 min.
The upstream and downstream oligonucleotide primers were chosen
on both sides of an intron to prevent ampliﬁcation of possible con-
taminating genomic DNA.
2.4. Western blots
BAT were minced with scissors in 10 volumes of an ice-cold ho-
mogenization buﬀer containing 25 mM sucrose, 12.5 mM Tris/HCl,
pH 7.4, and 0.06% protease inhibitor cocktail (Sigma, St Louis, MO).
They were then homogenized using a Teﬂon pestle in an ice-cold
Potter–Elvehjem homogenizer (clearance 0.11 mm, 10 up and down
strokes, 1800 r.p.m.). The homogenate was centrifuged at 1600· g for
10 min and the supernatant ﬁltered through 1 layer of surgical gauze
and centrifuged again at 35 000· g for 30 min. The ﬁnal supernatant
was kept for Western blot analysis. The protein concentration was
measured as described by Bradford [13] using the Bio-Rad Protein
assay (Bio-Rad Laboratories, Hercules, CA), with BSA as a standard.
Thirty micrograms of supernatant was dried under vacuum and re-
suspended in 10 ll of a loading buﬀer containing 20% glycerol, 6%
SDS and 0.02% bromophenol blue in 0.25 M Tris/HCl, pH 6.8.
Western blots were performed as previously described [14] using rabbit
polyclonal antibody #11211, which detects mouse 4E-BP1 and 4E-BP2[1] and a mouse monoclonal anti-glyceraldehyde phosphate dehydro-
genase (GAPDH) antibody (Chemicon International, Temacula, CA).
The signals were quantiﬁed by scanning photodensitometry as de-
scribed above.
2.5. Blood parameters
RIA kits were used for free T3 (ICN Pharmaceuticals, Orangeburg,
NY) and glucocorticoids (IDS, Boldon, UK) measurements.
2.6. Statistical analysis
Data are expressed as means ± S.E.M. Signiﬁcance was evaluated
using the unpaired Student’s t test.3. Results and discussion
The eﬀects of cold-exposure on UCP1 expression are medi-
ated by an activation of the SNS acting via the b-adrenoceptor
signaling system [2]. The degrees of expression of UCP1 and
4E-BP1 mRNA were ﬁrst compared in the BAT of WT mice
maintained at 24 C or exposed to 6 C for 48 h. As shown in
Fig. 1, cold-exposure increased UCP1 mRNA expressions 1.8-
fold, but decreased 4E-BP1 mRNA expression by 38% in the
BAT. Thus, cold-exposure induces an inverse modulation of
UCP1 and 4E-BP1 mRNA expressions in the BAT. These data
are the ﬁrst report of a regulation of 4E-BP1 mRNA expres-
sion in vivo. A regulation of 4E-BP1 expression has until now
been reported only in hematopoietic cell lines [15]. The ob-
served inhibition of 4E-BP1 expression reported in this study
could play a role in the upregulation of UCP1 upon cold-
exposure in mouse BAT.
Cold-exposure has been shown to induce the emergence of
brown adipocytes and an increase in UCP1 expression in the
WAT [16]. In fact, exposure to 6 C for 48 h induced a 2.6-fold
increase in UCP1 mRNA expression in the mouse parametrial
WAT [17]. This same treatment did not change 4E-BP1
expression in the parametrial WAT (100 ± 5% vs 97 ± 7% in
control as compared to 48 h cold-exposed mouse WAT,
Fig. 3. Northern blot quantiﬁcation of 4E-BP1 mRNA in the BAT
of WT, b1=b2-, or b3-adrenoceptor KO mice. The results are
means ± S.E. of arbitrary values normalized using the corresponding
18S rRNA values. They are expressed as percent of the controls.
n ¼ 6; *P < 0.05 vs respective control values.
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previously that the brown adipocytes present in the WAT
diﬀer from those in the BAT [17].
To test if the eﬀect of cold-exposure on 4E-BP1 mRNA
expression is, like that on UCP1, mediated by the b-adrenergic
signaling, we used the b-less mouse model generated in our
laboratory [10]. In the WT mouse BAT, UCP1 protein ex-
pression was increased 1.9-fold, whereas in the b-less mouse
BAT it was not signiﬁcantly modiﬁed after 48 h of cold-ex-
posure [10]. As shown in Fig. 2, 4E-BP1 mRNA expression
was similar in the BAT of WT and b-less mice. Cold-exposure
decreased 4E-BP1 mRNA expression by 45%, 60%, and 48%
after 2, 6 and 12 h, respectively. These results show that the
inhibition by cold-exposure of BAT 4E-BP1 expression is a
general phenomenon occurring in diﬀerent genetic back-
grounds. They also show that this inhibition is rapid, being
large and signiﬁcant already after 2 h at 6 C. In the BAT of b-
less mice, 4E-BP1 mRNA expression tended to increase
reaching a signiﬁcant value of 1.7-fold after 6 h of cold-
exposure. The suppression of the cold-exposure eﬀect in b-less
mouse BAT suggests that the inhibition of 4E-BP1 expression
is under the control of the SNS. The unexpected increase of
4E-BP1 expression after 6 h of cold-exposure suggests the
existence of other modulator(s) of 4E-BP1 expression.
The eﬀects of catecholamines on UCP1 expression are
known to be mediated in mouse BAT by the three b-adreno-
ceptor subtypes, the b3-adrenoceptor being predominant [18].
To determine the respective participation of the b1=b2- and of
the b3-adrenoceptor in the downregulation of 4E-BP1 ex-
pression in BAT, we used b1=b2- and b3-adrenoceptor KO
models. As shown in Fig. 3, in the BAT of the b1=b2-adre-
noceptor KO mice, 4E-BP1 mRNA expression was decreased
by 34% whereas, in the BAT of the b3-adrenoceptor KO mice,
it was increased 1.3-fold as compared to the respective WT
controls. These results suggest that the inhibitory eﬀect of the
b-adrenergic signaling on 4E-BP1 mRNA expression in the
BAT is not mediated by the b1=b2, but essentially by the b3-
adrenoceptor.
To conﬁrm the possibility that the downregulation of 4E-
BP1 mRNA expression is mediated by the b3-adrenoceptor, we
tested the eﬀect of the b3-adrenoceptor agonist CL 316 243 in
vivo. The expression levels of UCP1 mRNA and of 4E-BP1Fig. 2. Real time PCR quantiﬁcation of 4E-BP1 mRNA in the BAT of
WT ðdÞ and b-less ðsÞ female mice exposed to 6 C for 2, 6 and 12 h.
The results are means ± S.E. of arbitrary values normalized using the
corresponding cyclophilin A values. They are expressed as percent of
the values at time 0 in the WT mouse BAT. n ¼ 3)5; *P < 0.05 and
***P < 0.005 vs time 0 values.mRNA and protein in the BAT of CL 316 243 and saline in-
jected mice were measured. The administration of the b3-
adrenoceptor agonist BRL 26830A has been shown to induce a
rapid and transient increase in UCP1 mRNA expression in
BAT [19]. Similarly, as shown in Fig. 4, UCP1 mRNA levels
were increased 1.8-fold after 6 h and returned to near control
value 12 h after the injection of CL 316 243. 4E-BP1 mRNAFig. 4. Real time PCR quantiﬁcation of UCP1 and 4E-BP1 mRNA in
the BAT of C57BL/6J female mice 6 or 12 h after the intraperitoneal
injection of 1 lg/g of body weight of CL 316 243. The results are
means ± S.E. of arbitrary values normalized using the corresponding
cyclophilin A values. They are expressed as percent of the values
obtained in the saline injected controls. n ¼ 6; *P < 0.05 and
***P < 0.005 vs control values.
Fig. 5. Western blot quantiﬁcation of 4E-BP1 protein in the BAT
soluble fraction of C57BL/6J female mice 6, 12 or 24 h after the in-
traperitoneal injection of 1 lg/g of body weight of CL 316 243. The
results are means ± S.E. of arbitrary values normalized using the
corresponding glyceraldehyde phosphate dehydrogenase (GAPDH)
values. They are expressed as percent of the values observed in saline
injected controls. n ¼ 3; *P < 0.05 vs time 12 h value.
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injection, respectively. The b3-adrenoceptor seems therefore to
be largely involved in the control of 4E-BP1 expression by
cold-exposure. The b3-adrenergic stimulation of UCP1 tran-
scription is mediated by cyclic AMP and protein kinase A
(PKA) in a p38 mitogen-activated protein kinase (MAPK)-
dependent or independent manner [20]. It would be interesting
to know which PKA downstream component of the signaling
cascade participates in the downregulation of 4E-BP1 mRNA
expression.
We also measured the eﬀect of CL 316 243 in vivo on
4E-BP1 protein expression. As shown in Fig. 5, the level of 4E-
BP1 protein was maintained up to 12 h after CL 316 243 in-
jection, but fell by 41% 24 h after the injection. The decrease in
4E-BP1 protein expression is probably not involved in the
acute control of UCP1 expression by CL 316 243. It might
however play a role in the maintenance of an increased UCP1
expression upon the prolonged b3-adrenoceptor stimulation
occurring during cold-acclimation. It would be interesting to
investigate if 4E-BP1 phosphorylation is modulated by the
SNS and plays a role in the acute control of UCP1 expression
in the BAT.
The observation of a control of BAT 4E-BP1 expression by
catecholamines suggests that other hormones, involved in the
control of BAT thermogenesis, might participate in the mod-
ulation of 4E-BP1 mRNA expression. Interesting candidates
might be the thyroid hormone T3 and glucocorticoids. In BAT
cells, T3 has been shown to synergize with norepinephrine to
increase UCP1 expression [21] and glucocorticoids to inhibit
the eﬀect of norepinephrine on UCP1 expression [22]. In b-less
mice maintained at 24 C, the blood levels of T3 and of
glucocorticoids were found to be 1.3- and 1.6-fold higher, re-
spectively, than in WT controls (P < 0.05, n ¼ 5; results not
shown). Despite these increases, 4E-BP1 mRNA expressionwas not modiﬁed in the BAT of b-less as compared to WT
mice at 24 C (Fig. 2). This observation does not rule out the
possibility that T3 and glucocorticoids might play a role in the
control of 4E-BP1 expression upon cold-exposure.
The present study is the ﬁrst to describe a control of 4E-BP1
expression by the SNS. This control is in line with a possible
role of 4E-BP1 in the complex mechanism of the b3-adreno-
ceptor-mediated increase in BAT UCP1 expression.
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